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MaBACKGROUND Sphingosine-1-phosphate (S1P) is a constituent of high-density lipoproteins (HDL) that contributes to
their beneﬁcial effects. We have shown decreased HDL-S1P in coronary artery disease (CAD) but its functional relevance
remains unclear.
OBJECTIVES This study investigated the functional consequences of reduced HDL-S1P content in CAD and tested if
increasing it may improve or restore HDL function.
METHODS Human HDL from healthy and CAD subjects, as well as mouse HDL, were isolated by ultracentrifu-
gation. HDL-S1P-dependent activation of cell-signaling pathways and induction of vasodilation were examined
in vitro and in isolated arteries using native and S1P-loaded HDL, S1P receptor antagonists, and S1P-blocking
antibodies.
RESULTS HDL-S1P-dependent signaling was clearly impaired and S1P content reduced in CAD-HDL as compared to
healthy HDL. Both healthy and CAD-HDL could be efﬁciently and equally well loaded with S1P from cellular donors
and plasma. S1P-loading greatly improved HDL signaling and vasodilatory potential in pre-contracted arteries and
completely corrected the defects inherent to CAD-HDL. HDL-S1P content and uptake was reduced by oxidation
and was lower in HDL3 than HDL2. Loading with S1P in vitro and in vivo fully replenished the virtually absent
S1P content of apolipoprotein M-deﬁcient HDL and restored their defective signaling. Infusion of erythrocyte-
associated C17-S1P in mice led to its rapid and complete uptake by HDL providing a means to directly S1P-load
HDL in vivo.
CONCLUSIONS Reduced HDL-S1P content contributes to HDL dysfunction in CAD. It can be efﬁciently increased by
S1P-loading in vitro and in vivo, providing a novel approach to correcting HDL dysfunction in CAD. (J Am Coll Cardiol
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AB BR E V I A T I O N S
AND ACRONYM S
apo = apolipoprotein
CAD = coronary artery disease
CHO = Chinese hamster
ovarian cells
DOP = 4-deoxypyridoxine
eNOS = endothelial nitric
oxide synthase
ERK1/2 = extracellular signal-
regulated kinases 1/2
HDL = high-density lipoprotein
HNF 1A = hepatocyte nuclear
factor 1 alpha
HUVEC = human umbilical vein
endothelial cell
S1P = sphingosine-1-phosphate
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1471H igh-density lipoproteins (HDLs) confer pro-tection against the development of ather-osclerosis (1). In addition to their crucial
role in reverse cholesterol transport, HDLs have
several reverse cholesterol transportindependent
properties that potentially contribute to atheropro-
tection (2,3). Patients with clinically manifest athero-
sclerosis not only have low plasma HDL cholesterol
levels but their HDLs are dysfunctional and harbor
harmful metabolites (4). However, the reasons for
this dysfunction and the biochemical, structural,
and molecular correlates of HDL driving it are largely
unknown. Among the most frequently proposed
causes are oxidative modiﬁcations of HDL proteins
and lipids (5,6).
In previous work, we and others have shown that
HDLs contain sphingosine-1-phosphate (S1P) that
contributes to several beneﬁcial HDL effects, such as
nitric oxide-dependent vasodilation and car-
dioprotection (3,7–11). Recently, we have shown that
HDLs from patients with coronary artery disease
(CAD) contain considerably lower amounts of S1P
than healthy HDLs (12). However, it remains un-
known whether this reduced S1P content translates
into HDL dysfunction or, conversely, if increasing it
may improve or restore CAD-HDL function.SEE PAGE 1486In the present study, we investigated the func-
tional consequences of low S1P in CAD-HDL. We
compared activation of signaling pathways by healthy
HDLs and CAD-HDLs and have designed strategies to
increase HDL-S1P content in vitro and in vivo to
improve HDL function. We also examined whether
CAD-HDL signaling may be impaired due to low S1P
content and if this can be corrected by S1P-loading.
METHODS
A detailed description of all experimental procedures
is provided in the Online Appendix.
In brief, venous blood was drawn from healthy
human subjects (n ¼ 70) and patients with stable CAD
(n ¼ 64) recruited consecutively to expand the groups
used in our previous studies of S1P in CAD-HDL (12).
The study was approved by the ethics committee of
the University Hospital Essen and complies with the
Declaration of Helsinki. Written informed consent
was obtained from each participant. Demographic
and clinical data are provided in Online Table 1. HDLs
were isolated by sequential density gradient ultra-
centrifugation as described (12) from pooled plasma
(mice) or individual samples (humans).S1P was measured in plasma and HDLs
using liquid chromatography tandem mass
spectrometry (LCMS) (12) by blinded
investigators.
HDLs were loaded with S1P either by
incubation with sphingosine-laden human
erythrocytes (10 mmol/l sphingosine for 1 h) or
by adding 6 nmol S1P (in vitro studies) or 3
pmol S1P (vasodilation studies) to 0.1 mg
HDL.
C17-laden mouse erythrocytes (10 mmol/l
C17-S1P for 1 h) were extensively washed,
diluted to a hematocrit of 0.5, and injected
intravenously (150 ml).
STATISTICAL ANALYSIS. Data are expressed
by mean  SD or median (range) for contin-
uous variables and frequency count and per-
centage for qualitative variables, respectively. Groups
were compared by unpaired or paired Student t test,
Mann-Whitney U test, or chi-square test. Statistical
signiﬁcance was assumed for p < 0.05.
RESULTS
IMPAIRED CAD-HDL SIGNALING DUE TO LOWER S1P
CONTENT. We have previously shown that CAD-
HDLs contain lower S1P concentrations than HDLs
from healthy individuals in a total of 95 healthy
subjects and 85 patients with stable CAD (12). To test
whether this translates into impaired S1P-dependent
HDL signaling, we compared the effectiveness of
healthy HDL and CAD-HDL to activate 3 important
intracellular signaling cascades in human umbilical
vein endothelial cells (HUVEC): the extracellular
signal-regulated kinases 1 and 2 (ERK1/2) mitogen
activated protein kinases, the Akt pathway, and the
endothelial nitric oxide synthase (eNOS). We used
Western blotting to detect the active phosphorylation
sites of ERK1/2 (Thr202/Tyr204), Akt (Ser473), and
eNOS (Ser1177). HDL preparations from 14 healthy
subjects and 9 patients with stable CAD (Online
Table 2) were chosen randomly and compared. As
measured by LCMS, CAD-HDL contained 4 to 5 times
less S1P than healthy HDL (45.06  6.74 pmol/mg of
HDL protein vs. 273.78  15.01 pmol/mg; p < 0.05).
Using this experimental setup, we observed that CAD-
HDLs were much less efﬁcient than healthy HDLs in
activating all 3 kinases both in magnitude and dura-
tion of the evoked signaling response when used at
the same protein concentration (Figure 1A).
To test if the observed differences can be attrib-
uted to the differences in HDL-S1P content, we
established a cellular system in which S1P-dependent
FIGURE 1 Compromised Signaling by CAD-HDL Due to Lower S1P Content
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(A) Western blotting for activating phosphorylation of ERK1/2 (Thr202/Tyr204), Akt (Ser473), and eNOS (Ser1177) in HUVECs stimulated with healthy and CAD HDLs.
The S1P concentration present in an HDL-associated form is expressed as nmol/l (nM) of HDL-bound S1P for each HDL. (B) Western blotting for pERK1/2 and pAkt in
HDL-stimulated CHO-K1 and CHO-S1P1 cells. (C) HDL-induced ERK1/2 phosphorylation in the presence of increasing concentrations of the S1P1 antagonist W146.
(D) ERK1/2 and Akt activation by HDL after pre-blocking of HDL with the S1P-neutralizing antibody Sphingomab for 30 min. *p < 0.05. CAD ¼ coronary artery disease;
CHO ¼ Chinese hamster ovary; eNOS ¼ endothelial nitric oxide synthase; ERK1/2 ¼ extracellular signal-regulated kinases 1 and 2; HDL ¼ high-density lipoprotein;
HUVEC ¼ human umbilical vein endothelial cell; p ¼ phosphorylated; S1P ¼ sphingosine-1-phosphate.
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FIGURE 2 Disparities in HDL-S1P-Dependent Signaling Due to S1P Content Differences
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(A) Comparison of ERK1/2 and Akt activation by healthy and CAD-HDL. (B) No difference between ERK1/2 and Akt activation by individual pairs of healthy HDL and
CAD-HDL matched for an identical S1P content. *p < 0.05. Abbreviations as in Figure 1.
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1473HDL signaling can be reliably identiﬁed, quantiﬁed,
and compared among different HDL preparations. For
this, we used Chinese hamster ovarian (CHO) cells
that were rendered highly sensitive to S1P by stable
overexpression of the human S1P1 receptor (Online
Figure 1) and were thus expected to respond with
prominent S1P-dependent signaling to any S1P
associated with and presented by HDL. Indeed,
stimulation with HDL induced potent ERK1/2 and Akt
signaling responses in CHO-S1P1 cells compared to a
negligible one in control CHO-K1 cells (Figure 1B). We
then examined whether HDL-induced ERK1/2 activa-
tion was, indeed, dependent on the overexpressedS1P1 by adding the S1P1-speciﬁc antagonist W146 and
observed that it completely abolished ERK1/2 activa-
tion by HDL (Figure 1C). Finally, we directly showed
that the HDL signaling response was dependent on
their S1P content as pre-incubation of HDL with the
S1P-neutralizing antibody Sphingomab (13) abolished
the HDL signal in a concentration-dependent manner
(Figure 1D).
Comparing healthy and CAD-HDL signaling in
CHO-S1P1 cells revealed that CAD-HDLs were much
less efﬁcient in inducing ERK1/2 and Akt signaling,
similar to the results obtained in HUVEC (Figure 2A).
To test whether this may be caused by differences
FIGURE 3 S1P Uptake by HDL From Erythrocytes and Plasma
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(A) S1P-loading of HDL from erythrocytes. (B) Kinetic of S1P uptake by HDL (n ¼ 12) from erythrocytes. HSA was used for comparison (n ¼ 4). (C) S1P uptake by HDL
contained naturally in plasma after exposure to S1P-loaded erythrocytes. (1) Plasma and erythrocytes were separated. (2) Plasma were divided into pools a and b.
Erythrocytes (3) were incubated with sphingosine (4) to generate S1P, washed, and added (5) to plasma pool b for 30 min (6). Plasma and erythrocytes were then
separated (7, 8) and HDL isolated by ultracentrifugation (9). HDL was also isolated (10) from the unexposed pool b. (D) S1P levels in native and S1P-loaded plasma (left);
S1P content in native HDL and HDL isolated from S1P-loaded plasma (right). (E) ERK1/2 phosphorylation by native HDL and HDL isolated from S1P-loaded plasma. HSA ¼
human serum albumin; other abbreviations as in Figure 1.
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TABLE 1 Characteristics of HDL From Native and S1P-Loaded Human Plasma*
Native
Plasma
S1P-Loaded
Plasma
HDL Isolated
From Native
Plasma
HDL Isolated
From S1P-Loaded
Plasma
S1P, nmol/l 442  19 11,655  340† — —
HDL-C, mmol/l 1.4  0.2 1.0  0.1 — —
S1P/protein, pmol/mg — — 223  56 929  90‡
Cholesterol, mg/ml — — 0.56  0.07 0.46  0.05
S1P in the HDL fraction,
nmol/l plasma
393  74 954  97† — —
Values are mean  SEM. *Isolated from the same plasma at baseline and after incubation with S1P-loaded
erythrocytes. †p < 0.05 vs. native plasma. ‡p < 0.05 vs. native HDL.
HDL ¼ high-density lipoproteins; HDL-C ¼ high-density lipoprotein cholesterol; S1P ¼ sphingosine-1-
phosphate.
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1475other than those in S1P content, we compared
signaling by 6 pairs of healthy and CAD-HDL samples
that were speciﬁcally matched for the same S1P con-
tent (129.67  9.60 pmol/mg protein in healthy and
122.17  8.24 pmol/mg in CAD-HDLs) despite the
overall statistical difference in HDL-S1P between
groups (12). ERK1/2 and Akt phosphorylation by these
HDL-S1Pmatched pairs was virtually identical
(Figure 2B) suggesting that the poorer signaling
observed generally for CAD-HDL was, indeed, due to
their lower S1P content.
LOADING HDL WITH EXTERNAL S1P IMPROVES
SIGNALING AND VASODILATION. Next we addressed
whether and to what extent human HDL can take
up additional S1P. To do this, we incubated healthy
HDL with human erythrocytes, given that they are the
main physiological S1P sources in plasma (14) and
considering our observations that they release S1P
efﬁciently only in the presence of HDL (15). To evoke
rapid S1P release, we increased erythrocyte S1P
content w4-fold by short pre-incubation with sphin-
gosine (Figure 3A). After exposure to the erythrocyte
suspension, HDL rapidly and potently took up
S1P: HDL-S1P increased w10-fold after 10 min and
w20-fold after 45 min (Figure 3B). In comparison,
human serum albumin acquired 10-fold less S1P on a
protein basis (Figure 3B).
We then asked whether HDL contained naturally
in plasma can take up S1P and, if so, how much
would be taken up by the entire HDL plasma frac-
tion. To answer this, we isolated erythrocytes and
plasma from healthy individuals, S1P-loaded the
erythrocytes, and incubated them with their own
plasma (Figure 3C). HDLs were then isolated by ul-
tracentrifugation and their S1P content compared
with that of native HDLs from the same individual
(Figure 3C). As a result, plasma S1P increased
w10-fold (Table 1, Figure 3D), HDL-S1P 4.18-fold
(Figure 3D), and S1P associated with the entire HDL
fraction 2.43-fold (Table 1). This indicated that HDLs
in a normal plasma environment are highly efﬁcient
and potent acceptors of S1P. Interestingly, when
tested for ERK1/2 activation in CHO-S1P1 cells,
plasma S1P-loaded HDLs were more efﬁcient than
native HDL (Figure 3E).
To pursue this ﬁnding systematically, we tested
whether S1P-loading per se was able to improve HDL
signaling. To do this, we loaded HDL with S1P from
erythrocytes and stimulated CHO-S1P1 cells side by
side with native HDL. At all concentrations tested,
S1P-loaded HDLs were much more efﬁcient in acti-
vating ERK1/2 and Akt versus the corresponding
native HDL preparations (Figures 4A and 4B). This
was due to the increased S1P content as theS1P-neutralizing antibody Sphingomab was much less
efﬁcient in blocking signaling by S1P-loaded HDL
than native HDL (Figure 4B). Subsequent experiments
with human endothelial cells delivered similar
results: S1P-loaded HDL was much more effective
than native HDL in inducing ERK1/2 and eNOS
phosphorylation (Figure 4C). We also conﬁrmed that
in human endothelial cells, the S1P3 receptor is
required for HDL signaling (9) as the S1P3 inhibitor
TY52156 effectively blocked kinase activation by HDL
(Figure 4D).
We then transferred the in vitro observations to
functional arterial vasodilation studies that we per-
formed with healthy native and S1P-loaded HDLs in
explanted norepinephrine-pre-contracted rat mesen-
teric arteries. There, we observed that S1P-loading
clearly improved the vasodilator potency of HDL
(Figure 4E).
HDL-S1P, OXIDATION, AND HDL SUBCLASSES. CAD-
HDL is well known to differ from healthy HDL in
many structural and metabolic characteristics asso-
ciated with functional impairment (4,5). We thus
hypothesized that the ability of CAD-HDL to contain
and take up S1P may be compromised by CAD-
associated alterations of the HDL particle. To pursue
this experimentally, we examined if 2 such major
alterations—CAD-associated oxidative modiﬁcations
(4,5) and the prevalence of HDL3 versus HDL2 in CAD
(16)—have an impact on S1P content and uptake by
HDL. HDL oxidation resulted in a 44% loss of HDL-S1P
compared to native HDL (82  26 pmol/mg vs. 147 
77 pmol/mg) (Figure 5A). It also reduced S1P uptake by
HDL by more than 50% (Figure 5A). Western blot
analysis of apolipoprotein AI (apo AI) as the major
HDL apolipoprotein and apo M as an important S1P
binding partner in HDL (11) showed that both proteins
were altered by oxidation: apo M was virtually absent
in oxidized HDL, whereas apo AI appeared as several
FIGURE 4 S1P-Loading of Healthy HDL Augments Signaling and Vasodilator Potential
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FIGURE 5 Effects of HDL Oxidation and HDL Subclasses on S1P Content and Uptake Capacity
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FIGURE 6 HDL Lacking S1P Due to apo M Deﬁciency: Correction of Signaling by S1P-Loading
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TABLE 2 Characterization of Plasma and HDL in Mice Lacking apo M
HNF 1Awt HNF 1A -/-
HNF 1Awt
After DOP
HNF 1A -/-
After DOP
Plasma
S1P, nmol/l 1,233  56 772  61* 1,236  49 2,844  228†‡
HDL-C, mmol/l 1.95  0.5 4.2  0.3* 2.3  1.0 5.3  2.0
HDL
S1P/protein, pmol/mg 423  52 32  7* 238  62 376  149
Cholesterol/protein, mg/mg 0.5  0.1 0.5  0.03 0.4  0.01 1.0  0.5
Values are mean  SEM. *p < 0.05 vs. wild type. †p < 0.05 vs. the respective genotype without DOP. ‡p < 0.05
vs. wild-type mice with DOP (6 mg/l for 16 days).
-/- ¼ knockout mice; DOP ¼ 4-deoxypyridoxine, HNF 1A ¼ hepatocyte nuclear factor 1A; wt ¼ wild type; other
abbreviations as in Table 1.
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1479immunoreactive bands (Figure 5B). To then address
the issue of altered HDL subclass distribution in CAD
as a cause for lower HDL-S1P, we determined the S1P
content of HDL2 and HDL3 and measured their S1P
uptake. Interestingly, S1P levels were w2-fold lower
in HDL3 than HDL2 on a pmol per protein basis
(Figure 5C). Another difference became apparent after
S1P-loading: although both HDL2 and HDL3 took up
S1P efﬁciently, HDL3 took up 3.7-fold less than HDL2
(Figure 5C, right panel). No differences between apo
AI and apo M content were evident between HDL2 and
HDL3 (Figure 5D).
S1P-LOADING CORRECTS HDL DEFECTS IN apo
M DEFICIENCY. apo M is the main HDL protein that
binds S1P and apo Mdeﬁcient mice have severely
reduced HDL-S1P, along with distinct HDL signaling
defects (11). To test whether apo M may be a limiting
factor for S1P-loading of HDL, we examined S1P
uptake by apo Mdeﬁcient HDL (Figure 6A) iso-
lated from mice deﬁcient for hepatocyte nuclear
factor 1 alpha (HNF 1A), the transcription factor
indispensable for apo M gene expression (17,18). HNF
1A-/- HDL contained virtually no S1P (10-fold less S1P
per mg HDL protein than wild-type HDL) (Table 2,
Figures 6D and 6F), identical to what has been pub-
lished for genuine apo M-/- HDL (11), and featured a
similar defect in ERK1/2 activation (Figure 6E).
The signaling defect observed was due to the
lack of HDL-S1P and not to that of apo M as both
Sphingomab and S1P1 inhibitors abrogated ERK1/2
signaling by wild-type HDL (Figure 6C). This ex-
cluded apo M properties (other than its S1P-binding)
to be responsible for the signaling defects of apo
Mdeﬁcient HDL. Surprisingly, despite the complete
absence of apo M, HNF 1A-/- HDL efﬁciently acquired
S1P from erythrocytes in vitro and could be S1P-
loaded to the same extent as wild-type HDL
(Figure 6D). Of note, such S1P-loading completely
corrected the signaling defect of apo Mdeﬁcient
HDL (Figure 6E).
To test whether S1P-loading of HNF 1A-/- HDL
lacking apo M was also feasible in vivo, we treated
mice with low-dose 4-deoxypyridoxine (DOP), a
pharmacological inhibitor of the S1P-degrading
enzyme S1P lyase. Indeed, HDL-S1P increased w20-
fold and plasma S1P w3-fold, respectively, in HNF
1A-/- mice (Figure 6F, Table 2), reaching levels com-
parable with or exceeding those in DOP-treated
wild-type mice. Of note, the severe signaling
defect of HNF 1A-/- HDL was completely corrected
by DOP as shown by the similar effectiveness of
HDL from DOP-treated HNF 1A-/- and wild-type at
activating ERK1/2 (Figure 6G). These data suggestthat even HDLs with severe and inherent S1P
deﬁciency due to the lack of its main binding
protein in HDL (apo M) can be efﬁciently S1P-
loaded in vitro and in vivo, and that such S1P-
loading will completely correct the signaling de-
fects due to low HDL-S1P.
CONSEQUENCES OF S1P-LOADING FOR CAD-HDL
FUNCTION. As S1P-loading was possible both in S1P-
proﬁcient human and S1P-deﬁcient mouse HDLs, we
examined whether CAD-HDLs can also be S1P-loaded.
Using sphingosine-laden erythrocytes (0.1, 1 and 10
mmol/l), we observed that CAD-HDLs took up S1P
extremely well and did so as efﬁciently as healthy
HDLs (Figure 7A). Consequently, we tested if S1P-
loading of CAD-HDLs improved signaling potential.
Even the lowest S1P-loading dose of CAD-HDLs (593 
93 pmol S1P/mg taken up from 0.1 mM sphingosine-
laden erythrocytes) clearly enhanced ERK1/2 phos-
phorylation in CHO-S1P1 cells as compared with the
native CAD-HDL (297  101 pmol S1P/mg) (Figure 7B).
Thus, even a modest 2-fold increase in S1P content
was sufﬁcient to improve the signaling potential of
CAD-HDL. Also in human endothelial cells, S1P-
loading clearly enhanced the ability of CAD-HDL to
phosphorylate ERK1/2, Akt, and eNOS (Figure 7C).
Interestingly, when comparing signaling by S1P-
loaded healthy HDL and S1P-loaded CAD-HDLs,
signaling effectiveness of both was increased to the
same maximum extent (blue arrows in Figure 7D).
Finally, we observed that in norepinephrinepre-
contracted arteries, S1P-loaded CAD-HDL achieved a
similar or even better vasodilation at only one-tenth
of the corresponding native CAD-HDL concentration
(Figure 7E).
S1P-LOADING OF HDL BY ERYTHROCYTE TRANSFUSION.
To directly elevate HDL-S1P in vivo, we loaded
mouse erythrocytes with S1P ex vivo and injected
them intravenously into C57Bl6 mice (0.91  106 per
FIGURE 7 S1P-Loading of CAD-HDL Improves Signaling and Vasodilator Potential
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1481mouse) (Figure 8A). This corresponded to a
w9.4% increase in erythrocyte number (based on
9.65  106 erythrocytes/ml blood) and equaled a
dose of w0.9-1.7 nmol erythrocyte-associated S1P per
mouse.
To track the fate of injected S1P in vivo, we used
the synthetic C17-S1P analogue for loading, as it is
easily distinguished from its native C18-analogue
by LCMS. Five minutes after intravenous adminis-
tration, we collected plasma, isolated HDL, and
measured C17-S1P content. We found virtually 100%
of the injected C17-S1P in the HDL fraction (1.5 
0.09 nmol C17-S1P/mg HDL protein corresponding
to 1,038  0.06 pmol C17-S1P in the HDL fraction
based on 0.76 mg/ml HDL cholesterol in plasma,
0.6 mg HDL-cholesterol/mg HDL protein, and 2 ml
blood). Altogether, the total amount of S1P (C17-
and C18-) contained in HDL per mg protein
increased 4.5-fold compared to native HDL
(Figure 8B). Thus, S1P administered systemically
in vivo using S1P-loaded erythrocytes was acquired
predominantly by HDLs and efﬁciently increased
their S1P content.
DISCUSSION
HDLs from patients with manifest atherosclerotic
disease display several functional defects, such as
impairment of antioxidative and anti-inﬂammatory
properties (4,19). This has been attributed to alter-
ations of the HDL proteome and lipidome (4,6,20) as
well as HDL protein and lipid modiﬁcations (e.g.,
oxidation and glycation) (4,5). Recently, we have
shown that CAD-HDLs have lower S1P content than
healthy HDLs (12). Considering that HDL-S1P con-
tributes to several potentially atheroprotective
HDL effects (3,9,21,22) and our ﬁndings of CAD-
HDLimpaired S1P-dependent signaling, we suggest
that reduced S1P content may be another cause for
HDL dysfunction in CAD. Indeed, low HDL-S1P in(A) Time and concentration kinetics of S1P uptake by healthy HDL and
All loading times and concentrations resulted in HDL-S1P values higher
45 min, whereas those with 10 mM differed from all others at all times
10 min and 45 min for 0 mM sphingosine. (B) ERK1/2 and Akt activation
(the HDL loading was performed with 0.1 mM sphingosine-laden erythr
CAD-HDL (direct loading) from the same individuals in HUVEC. (D) ERK
CAD-HDL. The red arrowhead compares the response to healthy and C
contracted rat mesenteric arteries by native and S1P-loaded CAD-HDL (
lower protein concentration than native CAD-HDL to show their better
concentrations. The original tracings show the response to native CAD-H
Figure 1.
FIGURE 7 ContinuedCAD-HDLs translated into reduced ERK1/2, Akt, and
eNOS activation, both in S1P1-overexpressing CHO
cells and human endothelial cells. Additionally, the
potency of HDL-mediated vasodilation in intact ar-
teries depended on their S1P content.
Another novel observation was that healthy HDLs
and CAD-HDLs with the same S1P content were
equally efﬁcient in inducing signaling. This sug-
gested, at least in our system, that HDL signaling
was mainly dependent on their ability to carry,
retain, and present S1P. Accordingly, it is important
to uncover the molecular determinants of the lower
S1P content in CAD-HDL. Although alterations of
apo M may be the culprit (especially as its genetic
deletion in mice results in low HDL-S1P), variations
in plasma apo M have been excluded as a cause of
differences in plasma S1P (23), and we did not ﬁnd
HDLapo M content to differ between healthy and
CAD-HDLs (Online Figure 2). Here, we have shown
that a reduction of HDL-S1P can be caused by
oxidative modiﬁcations such as those known to
occur in CAD in vivo (4,5). Another cause of lower
S1P content in CAD-HDLs may be the prevalence of
HDL3 over HDL2 in CAD (16) because we observed
lower S1P content and inferior S1P uptake in HDL3
compared to HDL2. When expressed per mol HDL
instead of mg HDL protein (and considering the
lower molecular weight and higher protein concen-
tration of HDL3 compared to HDL2), our data align
with previous observations, in which HDL3 have
been shown to carry more S1P per mol (24).
Although apo M and apo AI were altered with HDL
oxidation, their levels were similar in HDL2 and
HDL3, thus excluding simple stoichiometric changes
in apolipoprotein/S1P ratios as plausible causes.
While the in vivo reasons for low S1P in CAD-HDL
need to be further characterized, the direct conse-
quence for us was to test whether CAD-HDL can
be loaded externally with S1P and whether this
compensated for innate signaling defects. We haveCAD-HDL from erythrocytes loaded with different sphingosine concentrations (n ¼ 3 each).
than those of native HDL. Values obtained with 0.1 and 1.0 mM sphingosine differed only after
. HDL-S1P was different between 10 and 20 min for 0 and 0.1 mM sphingosine, and between
by representative native HDL and low-dose S1P-loaded HDL (same individual) from Figure 7A
ocytes for 10 min). (C) ERK1/2, Akt and eNOS phosphorylation by native and S1P-loaded
1/2, Akt and eNOS activation by native and S1P-loaded (direct loading) healthy HDL and
AD-HDL before, and the blue arrowhead after S1P-loading. (E) Vasodilation of NEpre-
direct loading) from the same individuals. S1P-loaded CAD-HDLs were used at 10-fold
effectiveness. The chamber concentrations of HDL-S1P are depicted below the protein
DL at 0.3 mg/ml and S1P-loaded CAD-HDL at 0.03 mg/ml (10-fold less). Abbreviations as in
FIGURE 8 S1P-Loading of HDL by Erythrocyte Infusion
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1482provided afﬁrmative answers to both questions
(Central Illustration). We have excluded a role for
apo M in this process by showing that apo
Mdeﬁcient HNF 1A-/- HDLs containing virtually no
S1P could be successfully (and to the same extent as
control HDLs) loaded with S1P both in vitro and
in vivo and that this, too, corrected their severely
defective signaling. A recent study also showed that
HDLs from regular apo M-/- mice took up S1P nor-
mally from erythrocytes (25).
Most intriguing was our observation that increasing
HDL-S1P promotedHDL-mediated vasodilation both in
healthy HDLs and CAD-HDLs. This provided functional
relevance to our ﬁndings particularly in respect to
studies that have shown an impaired ﬂow-mediated
vasodilation (FMD) in CAD that was related solely to
low HDL cholesterol (26) and studies showing FMD
improvement by administration of reconstituted
HDL (27). Considering the speed and effectiveness by
which native HDL acquires S1P from cellular donors
or plasma, it is conceivable that administering re-
constituted HDL (devoid of S1P) would rapidly lead to
their uptake of S1P from the environment, thereby
improving the HDL-S1Pconveyed part of HDL-
mediated vasodilation. The concept of S1P-loading
of HDL to achieve better function is supported by
recent ﬁndings that S1P supplementation improved
the impaired ability of glycated HDL to induce
cyclooxygenase-2 in endothelial cells (28).
We have shown that S1P-loading of HDL can be
successfully achieved in vitro but also in vivo even
with apo Mdeﬁcient S1P-lacking HDL after phar-
macological inhibition of the S1P-degrading enzymeS1P lyase. Most importantly, in vivo loading
completely corrected the intrinsic HDL-signaling
defect in HNF 1A-/- mice caused by low HDL-S1P.
To apply this strategy in vivo (while circumventing
the undesirable effects of lyase inhibition or direct
S1P administration) (3) we injected S1P-loaded ery-
throcytes to preferentially increase HDL-S1P. This
administration route proved to be extremely efﬁcient
as almost all of the exogenous erythrocyte-
associated S1P was taken up by the HDL fraction af-
ter only 5 min. Furthermore, the 4- to 5-fold increase
of HDL-S1P we observed was high enough to equalize
any differences in S1P existing between healthy HDL
and CAD-HDL in humans and might thus sufﬁce to
improve CAD-HDL signaling in vivo.
Interestingly, previous research in anemic patients
receiving erythrocyte transfusion very similar to our
erythrocyte injection showed increased levels of
plasma and HDL-S1P (29), hinting at potential appli-
cability in humans. However, despite the efﬁcient S1P-
loading of HDLs in vivo, we do not know for how long
HDLs retain a therapeutically elevated S1P content.
Of note, intra-individual HDL-S1P concentrations
remain stable over a period of up to 18 months as we
have recently reported for CAD patients (30). Whether
S1P-loading will have an impact on general S1P-
dependent functions of HDL in vivo, such as car-
dioprotection, vasodilation, and cell survival (9,21,22),
will be the focus of future studies.
STUDY LIMITATIONS. CAD manifests with multiple
symptoms and grades of severity prompting us to
deﬁne clinical inclusion criteria (6 months without
CENTRAL ILLUSTRATION S1P-Loading Corrects HDL Dysfunction in CAD
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S1P is generated by phosphorylation of sphingosine by SK1/2 in red blood cells that store and release S1P for uptake by HDLs. In HDL, S1P binds to apo M (and possibly
other components when in excess). CAD-related modiﬁcations of HDL such as OX diminish HDL-S1P content resulting in impaired HDL-S1P signaling through endothelial
S1P receptors. CAD-HDL loading with S1P achieved by pharmacological blockade (DOP) of its degradation by the S1P lyase or by administration of S1P-loaded eryth-
rocytes replenishes HDL-S1P content and corrects HDL dysfunction. apo ¼ apolipoprotein; CAD ¼ coronary artery disease; DOP ¼ 4-deoxypyridoxine; HDL ¼ high-
density lipoprotein; OX ¼ oxidation; S1P ¼ sphingosine-1-phosphate; SK1/2 ¼ sphingosine kinases 1 and 2.
J A C C V O L . 6 6 , N O . 1 3 , 2 0 1 5 Sattler et al.
S E P T E M B E R 2 9 , 2 0 1 5 : 1 4 7 0 – 8 5 S1P-Loading Corrects HDL Dysfunction in CAD
1483the need for revascularization and clinically stable
disease). This selection bias has to be corrected in
the future by evaluating patients with other CAD
conditions as well as by population-wide studies.
CAD patients were under medication while controls
received none, and the effect of drugs on HDL-S1Premains unknown. Our systems were designed for
the highest possible sensitivity to S1P and thus do
not account for other functional differences be-
tween healthy and CAD-HDL. The measures we
have applied to increase S1P content in mice in vivo
are not easily transferable in humans. Ideally,
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: HDLs’
anti-atherogenic effects are mediated, in part, by the
bioactive lipid S1P. Dysfunctional HDL has been
implicated in the pathogenesis of atherosclerotic CAD,
and reduced S1P content is a cause of HDL dysfunc-
tion. Increasing S1P restores HDL function.
TRANSLATIONAL OUTLOOK: Clinical studies are
needed to investigate the efﬁcacy and safety of
increasing the S1P content of HDL in patients with CAD.
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1484FMD measurements should be used to correlate
(and, in case of HDL-S1Pincreasing therapeutic
intervention, monitor) vasoreactivity and HDL-S1P
content in the same individuals, both with normal
and impaired FMD. At the same time, these chal-
lenges deﬁne the next endeavors in this promising
research area.
CONCLUSIONS
We have shown that reduced HDL-S1P content con-
tributes to HDL dysfunction in CAD. Our ﬁndings
suggest that CAD-HDL can be efﬁciently loaded
with S1P, leading to HDL function comparable to
that of healthy HDL. This provides a potentially
novel therapeutic approach to the correction of HDL
dysfunction.
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